Pfützner A, Forst T, Ambrosch A, Schmitz H, Lichtwald K, Beyer J
Department of Endocrinology, Johannes-Gutenberg-University, Mainz, Germany.
Exp Clin Endocrinol Diabetes. 1995;103(2):123-5. doi: 10.1055/s-0029-1211340.
The serum of a stiff-man syndrome patient was declared international GAD reference standard at the "1st GAD Antibody Workshop" held at the "12th International Immunology and Diabetes Workshop" in Orlando, Florida, USA 1993. A comparative study was performed with 123 diabetic and non-diabetic patients to evaluate whether standardization of this reference serum had changed the properties of a commercially available ELISA assay. All samples classified positive with the old test were confirmed with the new assay. Four additional samples with high "normal" values became positive with the new test. One of them was a control person having a family history of diabetes and genetic loci DR4/DR11. These findings might implicate a higher risk for the development of IDDM. The new standardization and adaptation of the ELISA seems to have influenced the sensitivity of the test positively.
1993年在美国佛罗里达州奥兰多市举行的“第12届国际免疫学与糖尿病研讨会”上举办的“第一届谷氨酸脱羧酶抗体研讨会”宣布,一名僵人综合征患者的血清为国际谷氨酸脱羧酶参考标准。对123名糖尿病患者和非糖尿病患者进行了一项比较研究,以评估该参考血清的标准化是否改变了一种商用酶联免疫吸附测定(ELISA)检测方法的特性。所有用旧检测方法分类为阳性的样本在新检测中都得到了确认。另外四个“正常”值较高的样本在新检测中呈阳性。其中一个是有糖尿病家族史且具有DR4/DR11基因位点的对照者。这些发现可能意味着患胰岛素依赖型糖尿病(IDDM)的风险更高。ELISA的新标准化和调整似乎对检测的敏感性产生了积极影响。